ASCO 2012 Annual Meeting Highlights: Hematologic Malignancies

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 25, 2012
Expiration Date: June 25, 2013

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Community oncologists face a challenging diversity in the numbers and types of malignancies they treat on a weekly basis.  These specialists must be knowledgeable in numerous tumor types, with sufficient understanding to support appropriate clinical decisions regarding diagnosis, treatment and/or referral.  Furthermore, in both solid tumors and hematologic malignancies, new approaches to therapy, novel agents and combinations of agents, as well as ongoing clinical trials, all present a continuous stream of new data and information that busy clinicians must thoughtfully evaluate for appropriate inclusion into treatment plans for their individual patients.

Despite the need faced by community oncologists in treating this diverse array of malignancies, remaining current with new developments can be challenging.  This is especially true for cancers that are not among the most prevalent, and perhaps no more so than the hematologic malignancies. The American Society of Clinical Oncology (ASCO) meeting is one of the most important venues for the presentation of critical data and new research regarding numerous different types of malignancies. 

This activity is designed to provide community oncologists with updates specific to their needs of managing patients with leukemia, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma by providing an overview of clinical trial findings reported during the 2012 ASCO annual meeting held in Chicago (June 1– June 5) as reported by world-renowned experts in these specialties, including the implications of these data for community practice.

Target Audience

This activity is designed for physicians, physician assistants, pharmacists, and nurses who have an interest in enhancing their management of patients with blood cancers.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recall recent key clinical findings regarding efficacy, safety, and trial limitations for chronic myeloid leukemia (CML), non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma
  • Describe how recent clinical trial findings may impact practice including sequencing and tailoring therapy for CML, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma throughout the life cycle of these hematologic malignancies

Agenda

Emerging Combination Therapy Strategies for Non-Hodgkin’s Lymphoma John P. Leonard, MD

Advances in Leukemia: The Six-year Follow-up of Dasatinib Efficacy in Imatinib Resistant or Intolerant Patients Neil Shah, MD, PhD

Advances in Hodgkin’s Lymphoma Anas Younes, MD

Instructions for Participation and Credit
This activity is eligible for credit through June 25, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

John P. Leonard, MD
Professor of Medicine
Weill Cornell Medical College
Clinical Director
New York-Presbyterian Hospital
Weill Cornell Center for Lymphoma and Myeloma
New York, New York

Dr. John Leonard received his medical degree from the University of Virginia School of Medicine and completed his internship, residency, and fellowship in the Department of Medicine at New York Hospital-Cornell Medical Center. Dr. Leonard is currently professor of medicine, Weill Cornell Medical College, and clinical director, New York-Presbyterian Hospital/Weill Cornell Center for Lymphoma and Myeloma. In addition, he is chief, lymphoma/myeloma service, division of hematology and oncology, and director, hematology/oncology clinical research program.

Dr. Leonard holds memberships in several professional societies including American College of Physicians, American Federation for Clinical Research, American Society of Hematology, and American Society of Clinical Oncology. He is on the editorial board of Clinical Lymphoma and Myeloma, Blood, and Journal of Clinical Oncology, as well as the Scientific Advisory Board of the Lymphoma Research Foundation. Dr. Leonard works to try to improve cure rates for patients with lymphoma and myeloma and to improve remissions and extend life for other patients.

Neil P. Shah, MD, PhD
Associate Professor
Division of Hematology and Oncology
UCSF School of Medicine
San Francisco, California

Dr. Neil Shah received his PhD in microbiology and molecular genetics at the University of California, Los Angeles (UCLA), and his medical degree from the UCLA School of Medicine. He continued his postdoctoral training at UCLA with an internship and residency in internal medicine, followed by a fellowship in hematology and oncology. Dr. Shah is associate professor, Division of Hematology and Oncology at UCSF School of Medicine; co-leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center; and Edward S. Ageno Distinguished Professor of Hematology/Oncology, UCSF.

Dr. Shah is a diplomate of the American Board of Internal Medicine, American Board of Internal Medicine, and American Board of Internal Medicine. He has authored or co-authored numerous publications largely focused on chronic myeloid leukemia (CML), a disease of the hematopoietic pluripotent stem cell. Dr. Shah’s research interests focus on understanding molecular mechanisms of disease response, resistance and persistence in human CML.

Anas Younes, MD
Professor of Medicine
Director of Clinical and Translational Research
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed his residency in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. Dr. Younes is a professor of medicine and director of clinical and translational research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston. 

Board certified by the American Board of Internal Medicine and the American Board of Medical Oncology, Dr. Younes also holds memberships in the American Association of Cancer Research, American Society of Clinical Oncology, Southwest Oncology Group, and the American Society of Hematology. He has written numerous peer-reviewed articles and abstracts on relapsed/refractory Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), and his clinical and translational research is focused on the development of novel targeted therapy for these patients.

Accreditation

MediCom

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-315-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-315-284

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. John Leonard has received honoraria related to formal advisory activities and as a consultant from Abbott Laboratories; Biotest Pharmaceuticals Corporation; Calistoga Pharmaceuticals (now Gilead); Cell Therapeutics, Inc.; Celgene Corporation; GlaxoSmithKline plc; Hospira, Inc.; Immunomedics, Inc.; Johnson & Johnson Services, Inc.; MedImmune, LLC; Millennium Pharmaceuticals, Inc.; MorphoSys; Seattle Genetics, Inc.; sanofi-aventis U.S. LLC; and Teva Pharmaceuticals.

Dr. Neil Shah has received honoraria as a consultant from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis AG.

Dr. Anas Younes has received honoraria related to speakers’ bureau activities and as a consultant from Celgene Corporation, Novartis AG, Sanofi, and Seattle Genetics, Inc., in addition to consultant fees from Gilead. He has received grant support related to research activities from Affimed, Gilead, Novartis, Sanofi, and Seattle Genetics.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, medical director-oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Leonard has indicated that he does intend to discuss the use of lenalidomide + rituximab in combination as emerging combination strategies for non-Hodgkin’s lymphoma. This combination is in phase II study and has not been approved by the FDA for use in this patient population.

Drs. Shah and Younes have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Leonard, Shah, and Younes have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@practicaloncologist.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Teva Pharmaceuticals and Onyx Pharmaceuticals

©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.